Belzutifan

Overview

Belzutifan (PT2977) is an orally active and selective HIF-2α inhibitor with an IC 50 of 9 nM. Belzutifan, as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. Belzutifan is a potential treatment for clear cell renal cell carcinoma (ccRCC).

Application

Products | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > HIF/HIF Prolyl-Hydroxylase

Product Information

• Catalog No.: HY-125840
• CAS No.: 1672668-24-4
• Molecular Formula: C17H12F3NO4S
• Molecular Weight: 383.34
• Purity: 99.62%
• Storage: -20°C, stored under nitrogen * In solvent : -80°C, 1 year; -20°C, 6 months (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution
• Availability: In-stock

Source

Original product source